前列腺癌（PCa）仍然是發病和死亡的一個重要原因，病患帶有癌轉移腫瘤與較差的存 活率有關。我們研究的目標是確定新的治療策略並改善癌轉移患者的預後。採用多方面 的方法，結合臨床基因體分析、in vitro 和in vivo 實驗，發現前列腺癌（PCa）中新的致 癌驅動因素和轉移促進因素，我們專注於一個精氨酸 N-降解決定子途徑相關的基因， 稱為WDYHV1 (NTAQ1)。我們透過慢病毒轉染在LNCaP 前列腺癌細胞株過度表現該 基因，證明了該基因的致癌功能，例如刺激增殖、集落形成、3D 侵襲和跨孔遷移。並 且，我們發現WDYHV1 (NTAQ1)促進在NSG 免疫缺陷小鼠上的異質腫瘤生長與癌轉 移。轉錄體分析顯示有顯著差異的585 個基因表現，透過路徑分析表明，上調基因參與 上皮間質轉化 (EMT) 和透過NF-κB 進行的TNF-α 訊號傳導。這些發現凸顯了 WDYHV1 可作為開發減輕轉移性前列腺癌的標靶療法的有前途的候選基因。我未來的 研究將專注於透過驗證轉錄體分析的發現和與尋找精氨酸 N-降解決定子調節相關的 WDYHV 直接受質來闡明潛在致癌機制。;Prostate cancer (PCa) remains a significant cause of morbidity and mortality, and the presence of metastasis is linked to poor survival rates. The goal of our study is to identify novel therapeutic strategies and improve outcomes for patients with metastasis. A multifaceted approach was employed combining clinical genomic analysis, in vitro assays and in vivo assays to uncover novel oncogenic drivers and metastasis-promoting factors in prostate cancer (PCa) focusing on a specific gene associated with the arginine N-degron pathway, called WDYHV1 (NTAQ1). Via overexpression of WDYHV1(NTAQ1) in LNCaP prostate cancer cell line using lentiviral transduction, we demonstrated its oncogenic functions including stimulation of proliferation, colony formation, 3D invasion, and transwell migration ability. Furthermore, we found that WDYHV1(NTAQ1) promotes in vivo xenograft tumor growth and metastasis in NSG immunodeficient mice utilizing the luciferase / dTomato expression as the reporter. Transcriptome profiling uncovered that 585 genes upregulated dramatically and pathway analysis of these up-regulated genes indicated the involvement of epithelial-mesenchymal transition (EMT) and TNF-alpha signaling via NF-κB. These findings highlight the WDYHV1 gene as a promising candidate for developing targeted therapies to mitigate metastatic prostate cancer. My future studies will focus on elucidating the underlying oncogenic mechanism from transcriptome analysis and looking for potential direct WDYHV substracts associated with arginine N-degron regulation.
